Cardiorenal Syndromes Overview

Principles

Definition

Cardiorenal syndromes is an academic concept and research field focused on the complex, bidirectional interplay between heart and kidney dysfunction, where acute or chronic pathology in one organ system contributes to injury or failure in the other. This framework is crucial for advancing understanding, diagnosis, and treatment strategies for interdependent cardiovascular and renal diseases.

Ontological type

Pathophysiological Mechanisms

Therapeutic Strategies

Classification Systems

Key developments

Key Figures

Neurohumoral Paradigm era

Norman K. Hollenberg [1] was affiliated with Harvard University [3] and the University of California, San Francisco [4] during the Neurohumoral Paradigm era. His key contribution, as captured in the 1981 paper 'Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure' [6], clarified how the renin–angiotensin–aldosterone system tracks clinical state in congestive heart failure and framed the neurohormonal mechanisms driving heart–kidney interactions, legitimizing early trials targeting the RAAS. Wilson S. Colucci [2] was associated with the Harvard–MIT Division of Health Sciences and Technology [5] and with Harvard University [3] during this era. His contributions, highlighted by the same 1981 RAAS paper [6], helped translate neurohumoral concepts into clinically relevant risk stratification and consideration of ACE inhibitors and RAAS-targeted therapies for heart failure, underscoring the era's integrative cardiology–nephrology approach.

Venous Congestion Focus era

James B. Young [1], affiliated with Harvard University [3] and La Roche College [4], helped anchor the era’s venous congestion focus on renal dysfunction in advanced heart failure. His key contributions include highlighting venous congestion as a driver of renal impairment, demonstrated across papers such as Importance of Venous Congestion for Worsening of Renal Function in Advanced Decompensated Heart Failure [7], Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure [8], and The prognostic importance of different definitions of worsening renal function in congestive heart failure [9], which provided prognostic metrics and guided management strategies for this era. Peter A. McCullough [2], affiliated with University of Pennsylvania [5] and The University of Texas Health Science Center at San Antonio [6], contributed to recognizing cardiorenal risk as a critical clinical intersection. His work through Acute Renal Failure After Coronary Intervention [10], Cardiorenal risk: an important clinical intersection [11], and Cardiorenal Syndromes: An Executive Summary from the Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) [12] established definitions and a consensus framework that shaped diagnosis, risk stratification, and perioperative care in this venous-congestion–driven era [10][11][12].

Biomarker-Guided Integration era

W.H. Wilson Tang [1] is a leading cardiology scientist associated with Stanford University [3] and The University of Texas Southwestern Medical Center [4] during the Biomarker-Guided Integration era (2017-2023). His key contributions in this era include biomarker-guided phenotyping and integrated care strategies highlighted in Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association [6], which reframed diuretic management and outcomes around circulating markers and renal injury signals. Peter A. McCullough [2] is associated with Massachusetts Institute of Technology [5] and The University of Texas Southwestern Medical Center [4] during this era. His contributions align with Tang's, grounded in Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association [6], which structured biomarker-guided stratification and management in cardiorenal syndromes and underscored the translational potential for personalized therapies and inclusive outcomes.